Increased expression of the cellular oncogene 
and 42/6 antibody (anti-transferrin receptor), which impair the GU-*S transition in cycling cells, failed to inhibit c-myc expression and instead delayed the decrease in c-myc mRNA levels that normally occurs with the onset of DNA synthesis. These data indicate that c-myc is regulated (in normal lymphocytes) at several points in the cell cycle.
To date, many of the molecular events required for mitogenstimulated T cells to progress through the cell cycle have been elucidated. The data available indicate that after stimulation of resting (Go) peripheral blood mononuclear cell (PBMC) populations with mitogens, T cells enter G1 of the cell cycle, where they produce and express receptors for interleukin 2 (IL-2) (1). Interaction of IL-2 with IL-2 receptors on activated T cells is then required for expression of transferrin receptors (2) . The subsequent binding of transferrin to its receptor during late G1 of the cell cycle allows T cells to make the GU-YS transition.
Recently, Kelly et al. showed that stimulation of murine splenocytes with lectin mitogen concanavalin A, a T-cellspecific mitogen, or with lipopolysaccharide, a B-cellspecific mitogen, resulted transiently in increased levels of accumulated c-myc mRNA (3) . This increase occurred rapidly upon exposure of cells to mitogen, with c-myc mRNA levels reaching a plateau of 10-to 30-fold above resting levels within 2 hr and returning to baseline as the cells began synthesizing DNA. Similar results were reported for c-myc protein in human PBMC stimulated with the T-cell mitogen phytohemagglutinin (PHA) (4). Thus, expression of the c-myc protooncogene represents an early event of lymphocyte activation and may play a role in controlling the Go-+Gl transition in non-neoplastic T and B cells. Because the surface molecules involved in lectin mitogeninduced lymphocyte proliferation as well as the transmembrane signals generated upon binding of lectin mitogens to lymphocytes remain poorly characterized (5, 6), we determined the effect of several nonlectin mitogens on c-myc expression in human PBMC cultures. In addition, we used several immunosuppressive agents that inhibit proliferation of T cells to investigate their effects on c-myc mRNA levels in PBMC cultures stimulated with PHA, including (i) cyclosporin A (CsA), a fungal metabolite that selectively inhibits proliferation of T cells (7); (ii) dexamethasone, a synthetic glucocorticosteroid (8) ; (iii) anti-Tac antibody, which binds to IL-2 receptors (9); (iv) 42/6 antibody, which binds to transferrin receptors (2); and (v) OKT11A antibody, which binds to the sheep erythrocyte receptor present on all human T lymphocytes (10) . The data reported here provide evidence that c-myc mRNA levels can be regulated in PHA-activated T cells at numerous points in the G1 phase of the cell cycle.
MATERIALS AND METHODS
Reagents. Purified recombinant IL-2 (rIL-2) (lot LP-230B) was a gift of Cetus (Berkeley, CA) (11) . Units of IL-2 activity were assigned to rIL-2 preparations based on a bioassay using the CTLL-15H cell line (12) . Azide-free preparations of OKT3 and OKT11A monoclonal antibodies were obtained from Ortho Diagnostics, Monoclonal antibodies anti-Tac and 42/6, gifts of W. C. Greene (National Institutes of Health, Bethesda, MD) and I. Trowbridge (Salk Institute, La Jolla, CA), respectively, were purified by protein A affinity chromatography and stored in sterile phosphate-buffered saline solution (Difco) (pH 7.4). The origin and specificity of recombinant pBR322 placmids containing human c-myc cDNA (pRYC7.4), v-myb cDNA (KX162), and chicken (3-actin cDNA have been described (13) (14) (15) .
Cell Culture. PBMC were isolated from heparinized blood of healthy volunteers by Ficoll-Hypaque density gradient centrifugation. The composition of PBMC populations, determined by indirect immunofluorescence with cell-sorter analysis (16) , was 70%o-80% OKT3+, 75%-90% OKT11+, 1%-5% B7+, 5%-15% Ml+, 10%-20% OKIa+. PBMC were resuspended at a density of 2 x 106 per ml in complete medium [RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum/2 mM L-glutamine/penicillin (50 units/ml)/streptomycin (100 ,ug/ml)] and cultured in 75-cm2 flasks (Coming) in 5% C02/95% air at 370C in the presence Proc. Natl. Acad. Sci. USA 82 (1985) (PMA) (Chemical Carcinogenesis, Minneapolis, MN) (20 ng/ml), ionomycin (Calbiochem) (1 MuM), rIL-2 (10 units/ml), OKT3 (50 ng/ml), OKT11A (0.5 kug/ml), anti-Tac (0.2 pug/ml), 42/6 (2 pLg/ml), CsA (Sandoz) (1 1Lg/ml), dexamethasone (Sigma) (0.1 mM), hydroxyurea (Sigma) (1 mM). At the time of harvesting PBMC for RNA extractions, 0.1-ml aliquots were removed from flasks and plated in triplicate into microtiter wells containing 0.1 ml of complete medium. DNA synthesis in microtiter cultures was determined 72 hr after initiation of original bulk cultures by addition of 0.5 ACi of [3H]thymidine per well (6.7 Ci/mmol; 1 Ci = 37 GBq) for 8 hr (16).
HL60 cells, obtained from the University of Pennsylvania Cell Center, were grown at 2.5 x 105 cells per ml in complete medium.
RNA Blot Analysis. Total cellular RNA was isolated from PBMC by a guanidine isothiocyanate method (17) with cesium chloride modification (18) , quantified by absorbance at 260 nm, and 10-iug samples were denatured at 680C for 15 min in electrophoresis buffer (20 mM morpholinepropanesulfonic acid/5 mM sodium acetate/i mM EDTA/3% formaldehyde, pH 7.0) containing 50%o formamide. RNA was then subjected to electrophoresis through 1% agarose gels containing 6% formaldehyde and ethidium bromide at 2 ,ug/ml. Gels were visualized under UV irradiation to determine position of 28S and 18S rRNA bands and to assess integrity of RNA before transferring RNA to Gene Screen Plus filters (New England Nuclear). Filters were dried, baked at 80°C in vacuo, prehybridized at 42°C for 16-24 hr in prehybridization solution [50% formamide/1-x Denhardt's solution (0.02% Ficoll/0.02% polyvinylpyrrolidone/0.02% bovine serum albumin)/1% NaDodSO4/1 M NaCl/50 mM Tris-HCl, pH 7.4/heparin (0.5 mg/ml)/denatured salmon sperm DNA (250 ,ug/ml)/10% dextran sulfate], and hybridized at 42°C for 24 hr in the same solution containing 106 cpm per lane of heat-denatured plasmid DNA radiolabeled to high specific activity (0.5-1.5 x 109 cpm/,ug) with [a-32P]dCTP (3000 Ci/mmol) by a random primer method (19) . After washing twice in 2x NaCl/Cit (300 mM NaCl/30 mM sodium citrate)/0.1% NaDodSO4 at 25°C for 30 min and twice in 0.1x NaClI/Cit/0.1% NaDodSO4 at 50°C for 30 min, filters were exposed at -70°C for 24 hr to Kodak XAR film with intensifying screens. Autoradiograms were analyzed by laser densitometry at 600 nm (Corning 750).
RESULTS
PHA, OKT3, PMA, and Ionomycin Induce Elevations in c-myc mRNA Levels. Fig. 1 shows RNA blots of total cellular RNA extracted from PBMC cultured for 3 hr with lectin mitogen PHA, with nonlectin mitogens PMA and ionomycin, or with OKT3 monoclonal antibody. PHA induced a marked increased in the accumulated levels of c-myc mRNA (Fig.  LA) . DNA synthesis, measured at 72 hr, also increased, indicating that PHA-stimulated cells entered the cell cycle. The monoclonal antibody OKT3 also induced rapid increases in the levels of c-myc mRNA (Fig. LA) . This antibody binds to a 20-kDa glycoprotein molecule closely associated with the antigen receptor on human T cells (20) . Phorbol ester PMA, which binds to and activates protein kinase C in lymphocytes (21) , and calcium ionophore ionomycin, which presumably triggers lymphocyte proliferation by raising cytosolic free Ca2+ concentrations (22) , stimulated increases in the levels of c-myc mRNA at 3 hr that were comparable to those induced by PHA (see Fig. 1 B and C) . However, PMA and ionomycin induced somewhat less DNA synthesis at 72 hr. Because the majority of lymphocytes in unfractionated PBMC popula- The increase in c-myc mRNA levels in human T cells after stimulation with mitogens does not reflect a general increase in oncogene transcription, because levels of c-myb mRNA were unchanged in PBMC exposed to mitogens (Fig. 1D) . We chose c-myb as a control because the c-myc and c-myb protooncogenes are structurally similar based on sequence data (23) , and because the products ofboth ofthese genes are nuclear proteins (24, 25) . RNA extracted from HL60 cells served as a positive control in these experiments for detection of c-myc and c-myb mRNA with radiolabeled cDNA probes (26, 27) .
Effects of Inhibitors of Lymphocyte Proliferation on c-myc mRNA Levels. Fig. 2 shows RNA blots from several experiments in which PBMC were cultured for various times with PHA and an inhibitor. Results of scanning densitometry of autoradiograms in Fig. 2 are shown in Table 1 . OKT11A antibody, CsA, and dexamethasone inhibited the PHA-mediated increase in c-myc mRNA at both 3 hr (Fig. 2 A and D) and 24 hr (Fig. 2 B and E) . In contrast, anti-Tac antibody had little effect on c-myc mRNA levels at 3 hr (Fig. 2D ) but did produce reductions in c-myc mRNA levels at 24 hr ( Fig. 2E ; Table 1 ).
OKT11A, CsA, anti-Tac, and dexamethasone probably did not suppress transcription in PBMC nonspecifically, because levels of actin mRNA were not decreased (see Fig. 2C for OKT11A and CsA; others not shown). Although we cannot exclude the possibility that actin mRNA has a long half-life in T cells, we observed no decrease in levels of actin mRNA even after culture for 48 hr in the presence of inhibitors (unpublished observations).
Monoclonal antibody 42/6 and the DNA synthesis inhibitor hydroxyurea (28) did not decrease levels of c-myc mRNA measured in PHA-stimulated cells at 3, 12, 24, or 48 hr. In fact, these reagents caused increases in the relative levels of c-myc transcripts at 24 and 48 hr (see Fig. 2F for 42/6 at 24 hr and hydroxyurea at 48 hr; others not shown). By inhibiting the G1-*S transition, 42/6 and hydroxyurea appear to delay the decrease in c-myc mRNA levels that normally occurs with the onset of DNA synthesis. tc-myc mRNA levels at 48 hr (see Fig. 2G ).
FIG. 2.
Effects of inhibitors of lymphocyte proliferation on levels of c-myc mRNA. Total cellular RNA was isolated from PBMC after culture for 3 hr (A and D), 24 hr (B, C, E, and F), or 48 hr (G) with PHA-P and various inhibitors of lymphocyte proliferation. Lanes: 1, medium; 2, PHA (1 ,ug/ml); 3, PHA and OKT11A (0.5 ,ug/ml); 4, PHA and CsA (1 ,g/ml); 5, PHA and anti-Tac (0.2 Ag/ml); 6, PHA and dexamethasone (10-4 M); 7, PHA and 42/6 (2 jg/ml); 8, PHA and hydroxyurea (1 mM). After electrophoresis in 1% agarose gels (10 ug of RNA per lane) and transfer, filters were hybridized with 32P-labeled pRYC7.4 (c-myc) probe (13) . (C) Rehybridization with 32P-labeled actin cDNA probe (15) of blot from A after washing with 0.1% NaDodSO4/10 mM Tris-HCI, pH 7.4, at 650C for 1 hr. All inhibitors were used at concentrations that maximally inhibited PHA-induced proliferation of PBMC. Viability of PBMC was -90%o in all cultures, assessed by trypan blue dye exclusion.
Purified rIL-2 Augments Levels of c-myc mRNA. Because anti-Tac antibody interferes with IL-2-mediated events by binding to the IL-2 receptor, the data in Fig. 2 and Table 1 suggested that IL-2 might influence c-myc gene expression during G1 of the cell cycle. To test this hypothesis, we added rIL-2, PHA, both, or neither of these reagents to PBMC cultures before isolating RNA at 3 and 24 hr. As shown in Fig.  3 , rIL-2 alone had little or no effect on the levels of c-myc mRNA. In combination with PHA, however, rIL-2 produced increases in c-myc mRNA at 24 hr but not at 3 hr. The kinetics of this response to rIL-2 is consistent with the kinetics of expression of IL-2 receptors on PHA-stimulated T cells, because IL-2 receptors are not expressed until 6-8 hr and reach maximal levels at 2448 hr (29) .
DISCUSSION
The data reported here demonstrate that levels of c-myc mRNA are regulated in normal human T lymphocytes by various modulators of cell proliferation. The observation that OKT3 antibody induces rapid increases in c-myc mRNA suggests that increased expression of the c-myc protooncogene may be a normal physiological event of immune responses and not unique to stimulation of T cells with lectin mitogens in vitro.
Inhibitors of lymphocyte proliferation are valuable tools for dissecting the molecular events necessary for progression ofT cells through the cell cycle. The ability of OKT11A, CsA, and dexamethasone to diminish the PHA-induced accumulation of c-myc mRNA as early as 3 hr demonstrates that these immunosuppressive agents interfere with very early events of T-cell activation. The inhibition of IL-2 production and/or IL-2 receptor expression mediated by OKT11A, CsA, and dexamethasone may therefore represent indirect effects resulting from an early block in the sequence of T-cell activation events (7, 10, 30) . In this regard, it is of interest that lmmunology.-Reed et aL to c-myc mRNA accumulation is suppressed to a greater extent at 24 hr than at 3 hr in PBMC cultures containing OKT11A, CsA, or dexamethasone (Table 1) . Since IL-2 augments levels of c-myc mRNA at 24 hr, but not at 3 hr, in T cells stimulated by PHA (Fig. 3) , these inhibitory agents may influence c-myc mRNA levels both directly, by blocking transduction of PHA-induced signals to the c-myc gene, and indirectly, by impairing the production of IL-2. An alternative but not mutually exclusive explanation is that OKT11A, CsA, and dexamethasone may act at multiple points in the cell cycle to inhibit proliferation of T cells.
Using hydroxyurea and monoclonal antibody 42/6, we were able to dissociate increases in c-myc mRNA levels from proliferation of T cells (see Fig. 2 F and G and Table 1 ). By blocking the progression of PHA-stimulated T cells into S phase, hydroxyurea and 42/6 may prevent cells from reaching a point in the cell cycle where an unknown signal is generated that turns off c-myc gene expression.
The molecular signals directly responsible for changes in c-myc mRNA levels are a matter for speculation. The finding that rIL-2 increases c-myc mRNA accumulation in PHAstimulated T cells is of particular interest. Recently, it has been demonstrated that the binding of IL-2 to its receptor on T cells leads to protein kinase C activation (31) . PMA, by binding directly to the diacylglycerol allosteric site on protein kinase C, and ionomycin, by increasing cytosolic free Ca2+ concentrations, also may produce increases in protein kinase C activity (21) . Moreover, PHA and OKT3 may indirectly increase protein kinase C activity in T cells by stimulating phosphoinositol turnover and calcium influx, respectively (32, 33) . Protein kinase C could therefore represent the critical molecule that regulates levels of c-myc mRNA in normal T cells.
Previously, others have proposed that c-myc controls the G0oGl transition in normal lymphocytes (3) . Our data showing that IL-2 and various inhibitors of lymphocyte proliferation influence c-myc mRNA levels during G1 of the cell cycle, however, raise the possibility that c-myc may function at several points in the cell cycle to regulate lymphocyte proliferation.
